In a cohort of 7,657 unselected BC patients who tested negative for BRCA1/2 germline mutations, a multigene panel revealed that 29 cases (0.38%) carried harmful RAD51D germline mutations (Chen et al., 2018). This evidence concerns the gene RAD51D and breast cancer.